Nkarta Inc
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflam… Read more
Nkarta Inc (NKTX) - Total Liabilities
Latest total liabilities as of September 2025: $89.34 Million USD
Based on the latest financial reports, Nkarta Inc (NKTX) has total liabilities worth $89.34 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Nkarta Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Nkarta Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Nkarta Inc Competitors by Total Liabilities
The table below lists competitors of Nkarta Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai Longyun Advg & Media
SHG:603729
|
China | CN¥421.96 Million |
|
Adira Dinamika Multi Finance
JK:ADMF
|
Indonesia | Rp19.82 Trillion |
|
Sligro Food Group N.V.
PINK:SIGRF
|
USA | $1.03 Billion |
|
Jiangsu United Water Technology Co. Ltd. Cl A
SHG:603291
|
China | CN¥1.99 Billion |
|
Belpointe REIT Inc
OTCQX:BELP
|
USA | $44.51K |
|
Zhejiang Jindao Technology Co. Ltd.
SHE:301279
|
China | CN¥388.09 Million |
|
Axtel S.A.B. de C.V
OTCGREY:AXTLF
|
USA | $14.89 Billion |
|
Geospace Technologies Corporation
NASDAQ:GEOS
|
USA | $28.74 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Nkarta Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nkarta Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nkarta Inc (2018–2024)
The table below shows the annual total liabilities of Nkarta Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $93.23 Million | -11.72% |
| 2023-12-31 | $105.60 Million | +4.83% |
| 2022-12-31 | $100.73 Million | +339.18% |
| 2021-12-31 | $22.94 Million | +39.60% |
| 2020-12-31 | $16.43 Million | -77.77% |
| 2019-12-31 | $73.89 Million | +392.59% |
| 2018-12-31 | $15.00 Million | -- |